Nextpharma Logistics Gmbh Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Nextpharma Logistics Gmbh Pharmaceutical Import Records from India — 3 Products, $3.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nextpharma Logistics Gmbh — Pharmaceutical Importer Profile (2026) | 3 Products, $3.9M Trade | TransData Nexus

Nextpharma Logistics Gmbh

Pharmaceutical Importer · Germany · Diabetes & Endocrine Focus · $3.9M Total Trade · DGFT Verified

Nextpharma Logistics Gmbh is a pharmaceutical importer based in Germany with a total trade value of $3.9M across 3 products in 2 therapeutic categories. Based on 182 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Nextpharma Logistics Gmbh sources from 5 verified Indian suppliers, with Dr.reddy's Laboratories Limited accounting for 67.1% of imports.

Nextpharma Logistics Gmbh — Import Portfolio & Supplier Network

Nextpharma Logistics Gmbh import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Nextpharma Logistics Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr.reddy's Laboratories Limited	$9.1M	675	67.1%
Dr Reddys Laboratories Limited	$2.4M	93	17.8%
Dr Reddy S Laboratories Limited

What Formulations Does Nextpharma Logistics Gmbh Import?

Formulation	Value	Ships
Pregabalin beta 150 MG hart. kps 100	$150.0K	3
300023211 pregabalin beta 75 MG hart	$100.0K	2
Allobeta 300 tbl 100 (25104x100s=2510400nos)	$100.0K	2
Voriconazol beta 200MG ftb 100 (162x100s=16200 nos)	$100.0K	2
300023221 pregabalin beta 200MG hart.	$99.3K	3
Sitagliptin beta 100 MG ftb 98 (30541x98s=2993018 nos)	$95.2K	3
Sitagliptinmet. beta 50/1000MG ftp196 (8848x196s=1734208 nos)	$90.0K	2
Pregabalin beta 25 MG hart kps 100	$82.9K	2
Voriconazol beta 200MG ftb 50 (176x50s=8800 nos)	$80.3K	2
Ibubeta 400 akut ftb	$79.1K	2
Amlovalshct beta 10 320 25 MG ftb 98 de amlodipine valsartan hydrochlorthiazide 10 320 25 MG tablets 7 x 14s	$75.2K	2
Pregabalin beta 150 MG hart kps 100 (18792x100s=1879200 nos)	$71.2K	2
300037089 sitagliptin beta 100MG ftb	$68.8K	2
Pregabalin beta 75MG hart. kps 100 38843 x 100s packs=3884300	$65.6K	2
Sitagliptin beta 100 MG ftb 98 (17516x 98s=1716568 nos)	$58.9K	3

Nextpharma Logistics Gmbh imports 580 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sitagliptin	Diabetes & Endocrine	$2.8M	160	3.7%	7
2	Amlodipine	Cardiovascular	$550.0K	11	0.0%	7
3	Valsartan	Cardiovascular	$550.0K	11	0.3%	4

Nextpharma Logistics Gmbh imports 3 pharmaceutical products across 2 categories into Germany totaling $3.9M.

Nextpharma Logistics Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

NextPharma Logistics GmbH, established in 1992, was a prominent pharmaceutical logistics company headquartered in Bielefeld, North Rhine-Westphalia, Germany. The company specialized in providing comprehensive logistics services tailored for the healthcare sector, including storage, distribution, and transportation of pharmaceutical, medical, cosmetic, and dietary products. Serving clients across Germany, Austria, Switzerland, and beyond, NextPharma Logistics was recognized as one of the leading pharmaceutical logistics providers in the D-A-CH region.

In October 2025, NextPharma announced the sale of its logistics arm to Cencora, Inc., a global pharmaceutical solutions organization. This strategic divestment aimed to refocus NextPharma's efforts on its core competencies as a contract development and manufacturing organization (CDMO), positioning the company as Europe's leading pure-play CDMO. The transaction was completed in December 2025.

2Distribution Network

Prior to its acquisition, NextPharma Logistics GmbH operated a robust distribution network with multiple facilities across the D-A-CH region. The company's headquarters were located in Bielefeld, North Rhine-Westphalia, Germany. Additional sites included Werne and Holzwickede in Germany, Garching bei München, and Schaffhausen in Switzerland. These strategically positioned facilities enabled NextPharma Logistics to offer efficient and reliable logistics solutions to its diverse clientele.

3Industry Role

NextPharma Logistics GmbH played a pivotal role in the pharmaceutical supply chain as a specialized logistics service provider. The company focused on the storage, distribution, and transportation of pharmaceutical products, ensuring compliance with stringent industry standards and regulations. By offering tailored logistics solutions, NextPharma Logistics supported various stakeholders in the healthcare sector, including pharmacies, hospitals, laboratories, and pharmaceutical wholesalers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Nextpharma Logistics Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

NextPharma Logistics GmbH's sourcing strategy was characterized by a high degree of concentration, with a significant portion of its imports originating from a single supplier, DR.REDDY'S LABORATORIES LIMITED. This supplier accounted for approximately 67.1% of the total import value, amounting to $9.1 million across 675 shipments. Such a concentrated sourcing approach can present risks, including potential supply chain disruptions and dependency on a single supplier. However, the substantial volume of transactions suggests a stable and long-term relationship, which may mitigate some of these risks. The remaining imports were diversified among other suppliers, including DR REDDYS LABORATORIES LIMITED, DR REDDY S LABORATORIES LIMITED, MACLEODS PHARMACEUTICALS LIMITED, and ALEMBIC PHARMACEUTICALS LIMITED.

2Supply Chain Resilience

The resilience of NextPharma Logistics GmbH's supply chain was influenced by its sourcing concentration. While the primary supplier, DR.REDDY'S LABORATORIES LIMITED, provided a significant volume of products, the company's diversified supplier base, including DR REDDYS LABORATORIES LIMITED, DR REDDY S LABORATORIES LIMITED, MACLEODS PHARMACEUTICALS LIMITED, and ALEMBIC PHARMACEUTICALS LIMITED, contributed to mitigating potential risks associated with single-source dependency. The company's ability to manage a diverse range of formulations, with 580 unique formulations imported, indicates a level of flexibility and adaptability in its supply chain operations. However, the reliance on a single supplier for a substantial portion of imports suggests that any disruptions affecting this supplier could have a significant impact on the company's operations.

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the primary regulatory authority overseeing pharmaceutical imports is the Federal Institute for Drugs and Medical Devices (BfArM). The key legislation governing pharmaceutical imports includes the German Medicines Act (AMG), which outlines the requirements for the importation, distribution, and marketing of medicinal products. The marketing authorization pathway for Indian generics involves obtaining approval from the European Medicines Agency (EMA) or through national procedures, ensuring that imported generics meet the safety, efficacy, and quality standards set by European regulations.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Germany stipulate that all medicinal products must be authorized for sale within the European Union. This involves obtaining a marketing authorization from the EMA or a national competent authority. Good Manufacturing Practice (GMP) certificates recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S, are essential for ensuring product quality and safety. Additionally, wholesale distribution authorization is required for entities involved in the distribution of medicinal products, ensuring compliance with regulatory standards and maintaining the integrity of the pharmaceutical supply chain.

Quality & Labeling

Nextpharma Logistics Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

NextPharma Logistics GmbH's product category focus on diabetes and endocrine (71.6%) and cardiovascular (28.4%) therapeutic areas aligns with the significant market demand for these medications. The substantial import value of sitagliptin ($2.8 million) and amlodipine ($550,000) indicates a strategic emphasis on high-demand products within these categories. This focus suggests that NextPharma Logistics aimed to address prevalent health conditions in Germany, catering to a large patient population and meeting the needs of healthcare providers.

2Sourcing Profile

NextPharma Logistics GmbH's sourcing strategy was predominantly centered on generic drugs, with a significant portion of imports originating from India. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a focus on ready-to-market products that meet European quality standards. India's established pharmaceutical manufacturing capabilities and adherence to international quality certifications made it a key supplier for NextPharma Logistics, facilitating efficient procurement and distribution within the European market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Nextpharma Logistics Gmbh

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

The concentrated sourcing pattern of NextPharma Logistics GmbH presents an opportunity for new Indian suppliers to diversify the company's supplier base. By offering competitive pricing, reliable delivery schedules, and high-quality products, Indian exporters can position themselves as viable alternatives to existing suppliers. Demonstrating compliance with international quality standards and the ability to meet the company's specific logistical requirements would be crucial in establishing a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply NextPharma Logistics GmbH and the German market must obtain marketing authorization from the European Medicines Agency (EMA) or a national competent authority. Possessing GMP certificates recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S, is essential to ensure product quality and safety. Additionally, compliance with German labeling requirements, including German language labeling and serialization mandates, is necessary to meet regulatory standards.

3How to Approach

Frequently Asked Questions — Nextpharma Logistics Gmbh

What products does Nextpharma Logistics Gmbh import from India?

Nextpharma Logistics Gmbh imports 3 pharmaceutical products across 2 categories. Top imports: Sitagliptin ($2.8M), Amlodipine ($550.0K), Valsartan ($550.0K).

Who supplies pharmaceuticals to Nextpharma Logistics Gmbh from India?

Nextpharma Logistics Gmbh sources from 5 verified Indian suppliers. The primary supplier is Dr.reddy's Laboratories Limited (67.1% of imports, $9.1M).

What is Nextpharma Logistics Gmbh's total pharmaceutical import value?

Nextpharma Logistics Gmbh's total pharmaceutical import value from India is $3.9M, based on 182 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Nextpharma Logistics Gmbh focus on?

Nextpharma Logistics Gmbh imports across 2 categories. The largest: Diabetes & Endocrine (71.6%), Cardiovascular (28.4%).

Get Full Nextpharma Logistics Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.